Marketresearchnews

Tuesday, 11 May 2021

Impact of Existing and Emerging Global Healthcare Information Systems Market Trends And Forecast 2020-2027

The global healthcare information systems market is expected to register a CAGR of 10.0% during the forecast period of 2018 to 2023.

Healthcare information technology offers solutions for security and data management of information related with healthcare. Currently, information technology has more effect on the cost quality and safety associated with healthcare. Some commonly used applications in the healthcare industry include electronic medical records, healthcare records and personal health records.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7325

Healthcare Information Systems Market Segmentation

The global healthcare information systems market is segmented based on type, components, deployment, end user, and region.

On the basis of type, the market is segmented into hospital information systems, pharmacy information systems, laboratory information systems, medical imaging information system, revenue cycle management. The hospital information systems segment is sub-segmented into electronic health record, electronic medical record, real-time healthcare, patient engagement solutions, population health management and others. The pharmacy information systems segment is sub-segmented into prescription management, automated dispensing systems, inventory management and others. The medical imaging information System is sub-segmented into radiology information systems, monitoring analysis software, picture archiving & communication systems and others. Based on components, the market is divided into two, i.e., Software and Hardware. Based on deployment, the market is divided into web-based, on premise and cloud-based. By end user, the market is divided into hospitals, diagnostics centre, academic and research institution, and others. In the current scope of the study, the above-mentioned segments are covered into four global regions, namely- the Americas, Europe, Asia Pacific and the Middle East & Africa.

Healthcare Information Systems Regional Market Summary

The Americas dominated the global market of healthcare information systems. Rising demand for high quality diagnostics system is the main reason behind the supremacy of the North America’s healthcare information system market. Furthermore, large-scale implementation and storage of electronic records in the healthcare system witnessed in the countries such as Canada and the U.S is supporting the expansion of this regional healthcare information system market.

In 2017, it was estimated that Europe stood second in the global healthcare information systems market. This can be attributed due to the presence of a well-developed healthcare infrastructure, increasing awareness for the condition and presence of developed economies within the region.

Asia Pacific was the fastest growing region for the global healthcare information systems market in 2017. Asia-Pacific has a huge market potential for Healthcare IT industry. India and China are some of the rapidly growing countries, followed by South Korea. Consequently, the government in these rapidly developing economies have taken various efforts to improve healthcare services and provide better infrastructure.

On the other hand, the Middle East and Africa held least share in the global healthcare information systems market. Presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. Most of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-information-systems-market-7325

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Bioburden Testing Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Global Bioburden Testing Market is expected to grow significantly over the forecast period. It is estimated that the global bioburden testing market is expected to register a CAGR of Approx. 9.15% during the forecast period of 2018–2023 with an estimated market value of USD 455 million. Bioburden testing refers to an estimation of microbial load on a medical instrument, raw material, packaged goods among others. Bioburden testing is carried out to ascertain if the types and numbers of micro-organisms present are satisfactory or unsatisfactory when compared to predefined acceptance criteria.

Several factors such as increasing food safety concerns, rising medical spending, growing product recalls due to microbial contamination are expected to drive the growth of the market. The major players are involved in strategic collaborations and new product launches to strengthen their position in the market. For instance, in October 2018, SGS SA acquired IBR Inc., a non-clinical contract research organization (CRO). IBR Inc. focuses on integral services in biopharmaceutical analytics for the development of biologics, biosimilars and vaccines, and provides several filter testing and particle counting services.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6716

However, high costs of microbial enumeration instruments and complex and time-consuming regulatory standards in some economies may hinder the market growth during the assessment period. Also, test reports and certificates tend to be different from one country to another which hampers international trade. Therefore, in December 2017, International Organization for Standardization (ISO) published a new edition of ISO/IEC 17025 standard. This standard is an international reference for laboratories carrying out calibration and testing activities around the world. ISO/IEC 17025 helps facilitate cooperation between laboratories and other bodies by generating wider acceptance of results between countries.

Segmentation:

The global bioburden testing market has been segmented into test type, product type, application and end-user.

The market, on the basis of type, has been segmented into aerobic count, anaerobic count, fungi count and spore count.

The market, on the basis of product type, has been segmented into consumables and instruments.

The market, by consumables, has been sub-segmented into reagents and kits, and others.

The market, by instruments, has been further segmented into polymerase chain reaction machine (PCR), microscopes, and others.

The market, by application, has been segmented into raw materials testing, medical devices testing, in-process material testing, sterilization validation testing, and equipment cleaning validation.

The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, microbial testing laboratories, and others.

The market, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bioburden testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European bioburden testing market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The bioburden testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Bioburden Testing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

Charles River, SGS SA, WuXi AppTec, Merck KGaA, NORTH AMERICAN SCIENCE ASSOCIATES INC., Becton, Dickinson, and Company, Nelson Laboratories, LLC, Pacific Biolabs, ATS Laboratories, Inc., and Dynatec Labs are some of the major players in the global bioburden testing market.

Geographically, the Americas is anticipated to dominate the global bioburden testing market owing to a well-developed healthcare infrastructure, and growing healthcare expenditure. Moreover, favourable reimbursement scenario in this region fuels the growth of the market.

Europe is expected to hold the second largest position in the global bioburden testing market. The market growth in this region is attributed to the availability of funds for research.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and increasing government funding for healthcare sector. Also, there is a strong presence of major players in this region which boosts the market growth.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market share of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bioburden-testing-market-6716

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Research report covers the Artificial Neural Network Market Forecasts and Growth, 2020-2027

Market Scenario

The global artificial neural network market is expected to grow significantly over the forecast period. It is estimated that the global artificial neural network market is expected to grow significantly during the forecast period from 2018 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6287

An artificial neuron network is a computational model which resembles the function and structure of the human brain’s neuron system. The emergence of artificial intelligence and increasing adoption of the artificial neural network in the healthcare sector are the major drivers for the global artificial neural market. Factors such as the increasing healthcare expenditure, growing number of hospitalizations, and increasing prevalence of chronic diseases contribute to the growth of the market. Moreover, artificial neural networks provide significant benefits in medical research which is expected to fuel the market growth during the forecast period. Furthermore, owing to the growing adoption of artificial neuron network, many companies are engaged in developing artificial neuron network-based software. For instance, MAQ software by Microsoft implements an Artificial Neural Network (ANN) to learn from the historical data and predict the future values.

Despite the drivers, slow digitization across emerging economies and reluctance among healthcare professionals to adopt artificial intelligence-based technologies are likely to hamper the growth of the market during the assessment period.

Segmentation

The global artificial neural network market has been segmented into type, component, and application.

The market, on the basis of type, has been segmented into feedback artificial neural network, feedforward artificial neural network, and others.

The market, by component, has been segmented into software, services, and platform.

The global artificial neural network market, by application, has been segmented into clinical diagnosis and prognostics, image analysis and interpretation, bioelectric signal analysis and interpretation, drug development, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The artificial neural network market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European artificial neural network market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The artificial neural network market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The artificial neural network market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Neural Technologies Limited, SwiftKey, Starmind International AG, Afiniti, Ward Systems Group, Inc., SAP SE, NeuroDimension, Inc., Alyuda Research, LLC, Google Inc., Neuralware, Qualcomm Technologies, Inc., Intel Corporation, Microsoft Corporation, IBM Corporation, and Oracle Corporation are some of the key players in the global artificial neural network market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global artificial neural network market owing to a well-developed healthcare sector, due to the presence of a large number of enterprises in the development of neural network technologies, and high adoption advanced technology in the healthcare sector. According to the Centers for Disease Control and Prevention, in 2015, the total national health expenditure was USD 3.2 trillion.

Europe is expected to hold the second largest position in the global artificial neural network market. The market growth in this region is attributed to the growing adoption of artificial intelligence among healthcare providers and increasing healthcare expenditure coupled with the rising prevalence of chronic diseases.

The Asia-Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the accelerated economic growth of countries in the region and the growing need to control the increasing healthcare costs. These factors are also responsible for the emerging trend towards the digitization of patient records among healthcare organizations in this region.

The Middle East & Africa has the least share of the global artificial neural network market. However, this region is expected to have a potential growth opportunity for the artificial neural network market during the forecast period. The key factors driving the growth rate in this region include increasing technological implementations and rising healthcare investments.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/artificial-neural-network-market-6287

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Research report covers the Blockchain in Pharmaceutical Supply Chain Management Market Forecasts and Growth, 2020-2027

Market Scenario

The Global Blockchain in Pharmaceutical Supply Chain Management Market is expected to register a CAGR of 22.5% during the forecast period of 2019 to 2024.

A blockchain solution can make a substantive difference to the pharmaceutical supply chain. At every stage of the supply chain process, barcodes would be scanned and recorded onto a blockchain ledger system which, in sequence, records and creates an audit trail of the drug journey. Sensors can also be combined into the supply chain, with temperature or humidity being noted onto the ledger system. This is most important for drugs requiring fridge storage, such as insulin or expensive, specially manufactured medicines.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8009

Furthermore, through the use of blockchain, the supply chain process of the drugs can become more secure and streamlined. Every delivery can be tracked, with the delivery driver traced through biometric measures. Every checkpoint concerning the drugs supply is recorded and traced via biometric measures, 2d barcode scans, or sensor technology. As the drug is tracked from its manufacturing unit to the patient, the whole of the drug supply chain becomes seamless, precise, audited, and safe.

Segmentation

The global blockchain in pharmaceutical supply chain management is segmented on the basis of application, end user, and region.

On the basis of application, the global blockchain in pharmaceutical supply chain management market is segmented into product traceability, risk and compliance management, payment & settlement, others. The market by end user is segmented into manufacturers, distributors, healthcare providers

Key Players

Some of the key players in the Global Blockchain In Pharmaceutical Supply Chain Management Market are IBM, Microsoft, SAP SE, Oracle, Tibco Software, Auxesis Group, Omnichain, Vechain Foundation, Chainvine, Applied Blockchain, AWS, Huawei, Guardtime, BTL Group, Bitfury, Digital Treasury Corporation, Blockverify, Nodalblock, Peer Ledger, and others.

Regional Market Summary

The global blockchain in pharmaceutical supply chain management market is segmented on the basis of regions: Americas, Europe, Asia-Pacific, and the Middle East & Asia. The Americas account for the major share of the market owing to the well-developed technology, high healthcare expenditure, and the presence of the major pharmaceutical players. Europe accounted for the second largest market, which is followed by Asia-Pacific. Well-developed healthcare infrastructure and higher healthcare funds have driven the European blockchain in pharmaceutical supply chain management market. Asia-Pacific is the fastest growing blockchain in pharmaceutical supply chain management market. Rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market have paved the way for market growth. However, the Middle East and Africa holds the least share in the global blockchain in pharmaceutical supply chain management market. The presence of poor economies and low per capita income, especially within Africa, restrains the growth within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/blockchain-pharmaceutical-supply-chain-management-market-8009

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

New research report offers detailed research on developments in Hyperpigmentation Disorders Treatment Market 2027

Market Scenario

The global hyperpigmentation disorders treatment market analysis is accounted for USD 3,915 million in 2017 and expected to register 7.1% CAGR during the forecast period (2018–2023).

Hyperpigmentation disorder refers to harmless skin condition that causes darkened skin patches light brown to black in color. It is a common disorder of the skin and melasma is a common cause of facial hyperpigmentation. There are various types of hyperpigmentation, however, few of the most common such as melasma, solar lentigines, and post-inflammatory hyperpigmentation.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7462

The increasing demands for outpatient and minimally invasive

dermabrasion procedures, include augmented adoption of lasers in pigmentation disorders treatment and growing expenditure on the cosmetics across the world are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. According to the American Society of Plastic Surgeons, the number of dermabrasion cosmetic procedures have increased from 42,218 in 2000 to 88,182 in 2016 with a 109% increase during the estimated period.

The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the market during the assessment period.

Key Players

Some of the key players in the global hyperpigmentation disorders treatment market Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Inc., Galderma laboratories (Nestle Skin Health S.A), Obagi Cosmeceuticals LLC, Pierre Fabre, RXi Pharmaceuticals Corporation, SkinCeuticals International, and Vivier Pharma.

Intended Audience

Medical devices manufacturers
Pharmaceutical Companies
Medical devices product distributors and suppliers
Healthcare providers
Research institutes and academic centers
Government associations
Market research and consulting

Market Segmentation

The global hyperpigmentation disorders treatment market has been segmented on the basis of treatment type, disease indication, end-user, and region.

On the basis of treatment type, the market has been classified as topical drugs, chemical peels, microdermabrasion, laser therapy, phototherapy, and others. the market, by disease indication, has been segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. based on end-user, the market has been segmented into hospitals, aesthetic clinics & dermatology centers, and others. The topical drugs segment is expected to hold the largest market share of the hyperpigmentation disorders treatment market, by treatment type, during the forecast period. Also, by disease indication melasma segment register the considerable growth in comparison to other disease indication.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hyperpigmentation disorders treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European hyperpigmentation disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The hyperpigmentation disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hyperpigmentation disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas market is expected to be the second-largest hyperpigmentation disorders treatment market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, favorable reimbursement policies in American countries are contributing to the growth of the market in this region.

Europe is expected to be the third largest hyperpigmentation disorders treatment market during the forecast period owing to the rising in aging population. Moreover, the government of these countries are more focus to provide best treatment option to their citizen. According to the report published by world health organization, Europe aging population will increase from 14 million in 2016 to 19 million in 2020 and 40 million to 2050.

The market in the Middle East & Africa is expected to account for the smallest share of the global hyperpigmentation disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

The Asia-Pacific are likely to dominate the global hyperpigmentation disorders treatment market owing to the rising awareness of hyperpigmentation disorders, presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, Asia-Pacific is also expected to be the fastest-growing Hyperpigmentation Disorders Treatment market during the forecast period. According to the world bank group, in 2014, China spent 4.96% of gross domestic product (GDP) in healthcare expenditure, whereas in 2015, healthcare expenditure holds 5.32% of GDP. Also, in 2014, India spent 3.63% of GDP on healthcare, however, in 2015 healthcare expenditure holds 3.89% of GDP.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hyperpigmentation-disorders-treatment-market-7462

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

New research report offers detailed research on developments in Viral Vector Manufacturing Market 2027

Market Scenario:

Global viral vector manufacturing market size is expected to grow significantly over the forecast period. It is projected that the global viral vector manufacturing market is expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6890

Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.

However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.

Segmentation:

The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.

The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.

The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.

The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.

The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.

The market, by application, has been segmented into gene therapy and vaccinology.

The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Proteomics Market Growth, Trends and Value Chain 2020-2027

Market Scenario:

Upcoming Global Proteomics Market Trends expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 23.2 Billion in 2017 and is projected to grow at a CAGR of 14.1% over the forecast period. Proteomes are a set of proteins which are produced in a system, organism, or any biological entity. Study of proteomes is known as proteomics. It is used in various applications, like investigation of protein expression, transcriptional & post transcriptional studies, metabolic pathways, protein interaction in diseases, etc.

The factors such as increasing research & development activities in the healthcare industry, rising demand for personalized medicines, rising number of approvals of personalized medicines and increasing activities of drug discovery are expected to propel the growth of the market. According to Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicine therapies in 2017. However, the high cost of devices and lack of skilled researchers can hamper the market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6930

Segmentation:

The Global Proteomics Market has been segmented into equipment, service and applicationThe market, on the basis of equipment, has been segmented into chromatography, mass spectroscopy, protein microarray, x-ray crystallography, protein fractionation and others.The market, by services, has been segmented into laboratory services and data analysis & services. The laboratory services segment accounted for the largest market share owing to its benefits in effective diagnosis and research for drug discovery. Data analysis and services is expected to register the highest CAGR owing to increasing demand for data analytics.The market, by application, has been segmented into drug discovery, clinical diagnosis and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Proteomics Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Proteomics Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Proteomics Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Proteomics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

GENERAL ELECTRIC COMPANY, Bio-Rad Laboratories, Inc., Danaher, Siemens Ltd., Thermo Fisher Scientific Inc. Inc., Agilent Technologies, Inc., Genzyme Corporation, Biognosys AG, Bruker, Luminex Corporation, Merck KGaA, PerkinElmer Inc., WATERS, Caprion Biosciences Inc. and others are some of the key players in the Global Proteomics Market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global proteomics market owing to rising funding from government, rising awareness regarding applications of proteomics, cost effectiveness and increasing demand for personalized medicines. According to a report published in a journal named Leukemia Research in November 2017, personalized medicines improve life of cancer patients by 7 months at USD 32,000.

Europe is expected to hold the second largest position in the Global Proteomics Market. The market growth in this region is attributed to rising cancer research activities and government support. The proteomics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and the Rest of the Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing demand for personalized medicine due to rising prevalence of cancer and other such diseases and presence of large number of manufacturers of personalized medicines in the region. According to a report published by the National Institute of Cancer Prevention and Research (NICPR), around 2.25 million people in India are living with cancer in 2018.

The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/proteomics-market-6930

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com